

Gabriela Fois

Personal data

Name: Gabriela Fois
Date and place of birth: 06/05/1981, Seriate (BG), Italy
Citizenship: Italian
Work address: Center for the Study of Myelofibrosis,
IRCCS Policlinico S. Matteo Foundation V.le Golgi, 19, 27100 Pavia, Italy
Phone: +39038502487
Fax: +39038502876
E-mail: g.fois@smatteo.pv.it

Education

Master Degree in Neurobiology, University of Pavia, Italy
Bachelor Degree in Medical Biotechnology, University of Pavia, Italy

Current position

From January 2010 Fellowship in the Center for the study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo Pavia (Italy).

Technical skills and competence

Cell biology, Flow Cytometry, Immunohistochemistry and immunofluorescence techniques

Publication

- Zuccolo E., Bottino C., Diofano F., Poletto V., Codazzi A.C., Mannarino S., Campanelli R., **Fois G.**, Marseglia G.L., Guerra G., Montagna D., Laforenza U., Rosti V., Massa M., Moccia F. *Constitutive store-operated Ca²⁺ entry leads to enhanced nitric oxide production and proliferation in infantile hemangioma-derived endothelial colony forming cells.* Stem Cells Dev. 2015 Dec 9. [Epub ahead of print]
- Massa M, Canzonieri C, Campanelli R, Ornati F, **Fois G**, Pagella F, Matti E, Buscarini E, Danesino C, Rosti V, Olivieri C. *Increase of circulating endothelial cells in patients with Hereditary Hemorrhagic Telangiectasia.* Int J Hematol. 2015 Jan;101(1):23-31
- Avanzini MA, Bernardo ME, Novara F, Mantelli M, Poletto V, Villani L, Lenta E, Ingo DM, Achille V, Bonetti E, Massa M, Campanelli R, **Fois G**, Catarsi P, Gale RP, Moretta A, Aronica A, Maccario R, Acquafredda G, Lisini D, Zecca M, Zuffardi O, Locatelli F, Barosi G, Rosti V. *Functional and genetic aberrations of in vitro cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms.* Leukemia. 2014 Aug;28(8):1742-5
- Campanelli R, Rosti V, **Fois G**, Bonetti E, Barosi G, Massa M. *CD14brightCD16low intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis.* Exp Hematol. 2013 Dec;42(4):244-46
- Massa M, Rosti V, Campanelli R, **Fois G**, Barosi G. *Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.* Leukemia. 2014 Feb;28(2):449-51
- Rosti V, Villani L, Riboni R, Poletto V, Bonetti E, Tozzi L, Bergamaschi G, Catarsi P, Dalleria E, Novara F, Massa M, Campanelli R, **Fois G**, Peruzzi B, Lucioni M, Guglielmelli P, Pancrazzi A, Fiandrino G, Zuffardi O, Magrini U, Paulli M, Vannucchi AM, Barosi G. *Spleen endothelial cells from patients with Myelofibrosis harbor the JAK2V617F mutation.* Blood 2013 Jan;121(2):360-8
- Massa M, Campanelli R, Lupo L, **Fois G**, Viarengo G, Jemos V, Rosti V, Barosi G. *Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34(+) haematopoietic progenitor cells in primary myelofibrosis.* Br J Haematol. 2011 Mar;152(5):665-7